CONNEXT CO., LTD
- Biotech or pharma, therapeutic R&D
CONNEXT is a clinical-stage biotech company focusing on the development of CNT201 (recombinant collagenase) and CNT101 (recombinant toll-like receptor 5 agonist). The US FDA cleared a Phase I/II IND for CNT201 for the treatment of Dupuytren's contracture, and the dose escalation (Phase 1) part was successfully completed. Top-line data for the entire study is planned for the first half of 2026. The Phase 1 IND for CNT101 has been cleared for acute graft-versus-host disease (aGvHD).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}